Issue link: https://uberflip.scri.com/i/1529641
1125/24SCR018-7/R3 Abstract & Presentation Calendar ASH® 2024 7 Saturday Sunday Monday MONDAY, DECEMBER 9 TH 10:30am - 6:00pm Pacific Time Time Presentation Time Session Location Presentation Type Abstract Number Presentation Title 1st Author *SCRI First Author in Bold SCRI-Affiliated Coauthors Session Name 10:30am - 12:00pm 11:15am Marriott Marquis, Pacific Ballroom Salons 21-22 Oral 772 Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/ Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial Hungria V Rifkin R Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma 2:45 - 4:15pm 3:30pm Marriott Marquis San Diego Marina, Pacific Ballroom Salons 15-17 Oral 868 Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed/Refractory Diffuse Large B-cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T– naive and CAR-T–exposed Patients Gaballa S Ramakrishnan A Aggressive Lymphomas: Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications 2:45 - 4:15pm 3:30pm Marriott Marquis, Marriott Grand Ballroom 5-6 Oral 886 BRUIN CLL-321: Randomized Phase III Trial of Pirtobrutinib Versus Idelalisib Plus Rituximab (IdelaR) or Bendamustine Plus Rituximab (BR) in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Sharman JP Sharman JP, Burke JM Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Treating Refractory Disease-Novel Agents and Quality-of-Life 2:45 - 4:15pm 3:30pm San Diego Convention Center, Hall B Oral 922 Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Proteinâ€"Coupled Receptor Class C Group 5 Member D (GPRC5D)â€"Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM) Bal S Gregory T Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Emerging Targeting Approaches of Cell Therapies for Hematologic Malignancies 4:30 - 6:00pm 5:00pm Marriott Marquis, Marriott Grand Ballroom Oral 963 Obecabtagene autoleucel (obe-cel) for Adult Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Deep Molecular Remission May Predict Better Outcomes Jabbour E Shaughnessy P Acute Lymphoblastic Leukemias: Therapies Excluding Allogeneic Transplantation: Risk Stratification and CAR-T Therapies